Viperin interacts with the kinase IRAK1 and the E3 ubiquitin ligase TRAF6, coupling innate immune signaling to antiviral ribonucleotide synthesis

Arti B. Dumbrepatil, Soumi Ghosh, Kelcie A. Zegalia, Paige A. Malec, J. Damon Hoff, Robert T. Kennedy, and E. Neil G. Marsh

From the Departments of Chemistry, Biophysics, and Biological Chemistry, University of Michigan, Ann Arbor, Michigan 48109-1055

Edited by Peter Cresswell

Viperin interacts with the kinase IRAK1 and the E3 ubiquitin ligase TRAF6, coupling innate immune signaling to antiviral ribonucleotide synthesis. Viperin is unusual in being one of only eight radical SAM enzymes found in animals. The vast majority of the now over 100,000 radical SAM enzymes predicted by sequence analyses catalyze reactions unique to microbial metabolism, which are initiated by the reductive cleavage of SAM to generate a 5'-deoxyadenosyl radical. Viperin shows that it adopts the canonical (βα)₈-partial barrel-fold observed for radical SAM enzymes, in which the catalytically essential [4Fe-4S] cluster is ligated by the three cysteinyl residues of the hallmark CXXXCCXC motif. The structure of mouse viperin shows that it is comprised of an N-terminal membrane-associated domain and a C-terminal cytosolic domain. The enzyme's antiviral effects are not readily explained by the production of the antiviral nucleotide ddhCTP.
influenza A infection (21), and ddhCTP was ineffective as a chain terminator for RNA polymerases from picornaviruses such as poliovirus and human rhinovirus (20). Furthermore, there is a large body of evidence linking viperin’s antiviral properties to interactions with a variety of host and viral proteins that may play a role in down-regulating or inhibiting metabolic pathways important for viral replication (7, 9, 21–25). Viperin’s interactions with these proteins is not obviously related to the production of ddhCTP.

In particular, viperin plays an important role in innate immune signaling as a component of the Toll-like receptor 7 (TLR7) and TLR9 pathways that leads to type I interferon production (26, 27). TLR7 and TLR9 are among various pattern recognition receptors that sense viral nucleic acids and induce production of type I interferons by plasmacytoid dendritic cells to protect the host from viral infection (1). As a component of this pathway, viperin stimulates the K63-linked poly-ubiquitination of interleukin-1 receptor-associated kinase (IRAK1) (28–30) by the E3 ubiquitin ligase, TRAF6 (27, 29). K63-linked poly-ubiquitination, in turn, activates IRAK1 to phosphorylate interferon regulatory factor 7 (IRF7), causing IRF7 to migrate to the nucleus where it activates transcription of type 1 interferons (30, 31) (Fig. 1A).

The fact that viperin is a component of this signaling pathway suggested to us that its enzymatic activity might be regulated by interactions with its partner proteins. To examine this possibility, we reconstituted the interactions between viperin, IRAK1, and TRAF6 that lead to poly-ubiquitination of IRAK1 in HEK 293T cells. Our experiments demonstrate that IRAK1 and TRAF6 activate viperin toward reductive cleavage of SAM and the production of ddhCTP. At the same time, viperin stimulates the ubiquitination of IRAK1 by TRAF6, in a manner that is SAM-dependent. The synergistic activation of these enzymes provides a mechanism to couple innate immune signaling to the production of antiviral ribonucleotides.

**Results**

It has not proved possible to solubly over-express full-length IRAK1 and TRAF6 in *Escherichia coli*, although various subdomains of these proteins have been successfully produced (28, 32, 33). This is most likely because both enzymes are multidomain human proteins, most of which are notoriously recalc-
transient to expression in recombinant bacteria. Partly for this reason, and because it is not clear which domains of these proteins interact with viperin, we decided to study the interactions between viperin, TRAF6, and IRAK1 in a cellular context. Expression in eukaryotic cells allowed viperin to localize to the ER membrane and lipid droplets, which studies suggest may be important for its function (7, 34), and allowed the effect of viperin on the poly-ubiquitination of IRAK1 by TRAF6 to be examined.

Viperin, IRAK1, and TRAF6 were co-transfected in HEK 293T cells and their expression analyzed by immunoblotting. All three proteins were co-expressed, although as evident in Fig. 2a, the cellular levels of viperin were lower when IRAK1 and TRAF6 were co-expressed with viperin (Fig. S1). The expression levels of TRAF6 or IRAK1 remained similar, regardless of whether the other two enzymes were co-expressed (Fig. 2, b and c). Similar patterns of expression were observed when the catalytically inactive mutant, viperinΔ3C (in which the cysteine ligands that bind the iron-sulfur cluster are mutated to alanine) was co-expressed with IRAK1 and TRAF6 (Fig. S2).

**IRA1K and TRAF6 synergistically activate viperin**

As enzymes in signaling pathways typically function by activating or repressing the activity of other enzymes, the involvement of viperin in the TLR7/9 signaling pathways suggested that the enzymatic activity of viperin may be regulated by IRAK1 and/or TRAF6. Therefore, we examined the effects of IRAK1 and TRAF6 co-expression on the enzymatic activity of viperin. Cell extracts were prepared under anaerobic conditions (due to the in vitro oxygen-sensitivity of radical SAM enzymes) from HEK 293T cells co-transfected with viperin, IRAK1, and TRAF6. The enzymatic activity of viperin was quantified by measuring the formation of 5′-dA, as described under “Experimental procedures” and the amount of viperin present in the cell extracts was quantified by immunoblotting (Fig. S3).
When assayed in the absence of exogenous CTP, cell extracts expressing only viperin exhibited low levels of activity, with an apparent turnover number, $k_{\text{obs}} = 0.94 \pm 0.05 \text{ h}^{-1} \ (\text{Fig. 2D, Table S1})$. This basal activity is likely due to low concentrations of endogenous CTP in the cell extract. Negligible amounts of 5'-dA were formed in cell extracts lacking viperin or in cells expressing viperinΔ3C. Surprisingly, when the co-substrate CTP (300 μM) was added to the assay, only a modest 2.4-fold increase in activity ($k_{\text{obs}} = 2.38 \pm 0.05 \text{ h}^{-1}$) was observed. For comparison, previous experiments on N-terminal truncated rat viperin, expressed and purified from E. coli, had found CTP stimulated 5'-dA formation ~130-fold (20).

In contrast, when lysates prepared from cells co-expressing IRAK1 and TRAF6 were assayed, viperin activity with CTP as substrate increased ~10-fold (Fig. 2D). Under these conditions $k_{\text{obs}} = 21.4 \pm 1.6 \text{ h}^{-1}$, which is 2-fold higher than the apparent $k_{\text{cat}}$ reported for truncated rat viperin (20). In the absence of exogenous CTP, the basal level of viperin activity was increased 4-fold ($k_{\text{obs}} = 4.30 \pm 0.21 \text{ h}^{-1}$) by co-expression with IRAK1 and TRAF6, consistent with these proteins activating viperin. Expression of viperin with IRAK1 alone resulted in lower levels of activation, whereas co-expression of viperin with TRAF6 alone had no effect on viperin activity. Further experiments confirmed that CTP was converted into ddhCTP by viperin (Fig. 2E) and that when deuterated CTP was used as the substrate, deuterium was transferred to 5'-dA, which is consistent with the postulated mechanism for ddhCTP formation. We also note that in cell extracts ATP, but not GTP or UTP, had a similar stimulatory effect on 5'-dA formation ($k_{\text{obs}} \sim 2.4 \text{ h}^{-1}$) observed for comparison, previous experiments on N-terminal truncated rat viperin, expressed and purified from E. coli, had found CTP stimulated 5'-dA formation ~130-fold (20).

\textbf{IRAK1 mediates interactions between viperin and TRAF6}

To examine whether the activating effect of IRAK1 and TRAF6 is associated with viperin, IRAK1, and TRAF6 forming a complex, we conducted immunoprecipitation experiments using either FLAG-tagged viperin or Myc-tagged IRAK1 as bait proteins. Immunoprecipitation experiments were conducted on HEK 293T cells transfected with all three proteins and with extracts of cells singly transfected with viperin, IRAK1, or TRAF6. For singly transfected cell extracts these were combined in a 1:1:1 ratio and incubated for 30 min at 4°C before being subjected to immunoprecipitation. The bait protein was then immunoprecipitated with the appropriate antibody. Both sets of experiments yielded similar results (Fig. 3).

With viperin as bait, IRAK1 co-precipitated independently of TRAF6; however, TRAF6 only co-precipitated in the presence of both viperin and IRAK1 (Fig. 3A, Fig. S5a). Consistent with these results, when IRAK1 was used as bait both viperin and TRAF6 were co-precipitated independently of each other (Fig. 3b, Fig. S5b). These observations imply that IRAK1 binds to both TRAF6 and viperin to mediate complex formation, whereas viperin and TRAF6 do not independently associate with each other. Similar results were obtained when viperinΔ3C was used as the bait protein, which suggests that the iron-sulfur cluster is unnecessary for IRAK1 to bind viperin.

The N-terminal domain of viperin serves to localize the enzyme to the cytoplasmic face of lipid droplets and the ER (13), whereas TRAF6 and IRAK1 are cytosolic enzymes (35). Consistent with the immunoprecipitation results, we observed that co-expression of viperin with TRAF6 and IRAK1 caused these enzymes to re-localize to the ER membrane as determined by immunofluorescence microscopy of fixed and immunostained cells (Fig. 4).
Ubiquitination of IRAK1 requires viperin

Given that IRAK1 and TRAF6 appeared to activate viperin toward the production of dhdCTP, we were interested to know whether, conversely, viperin stimulated the ubiquitination of IRAK1 by TRAF6. Viperin was initially implicated in the K63-linked poly-ubiquitination of IRAK1 by TRAF6 based on studies that used mouse-derived viperin and/or TRAF6 and human plasmacytoid dendritic cells. The TLR7/9 signaling pathways were stimulated in these cells with either dsRNA or lipopolysaccharides to induce viperin expression (26, 27). However, these studies did not address the mechanism by which viperin facilitates immune signaling.

Preliminary evidence that viperin stimulates the poly-ubiquitination of IRAK1 was provided by the observation of high molecular weight isoforms of IRAK1 in immunoblots of cells transfected with viperin, IRAK1, and TRAF6 (Fig. 2B). When immunoblots were probed with anti-ubiquitin antibodies, viperin was found to significantly stimulate ubiquitination of IRAK1. Similar results were found when IRAK1 was first immunoprecipitated from cell extracts and the recovered protein then analyzed by immunoblotting with anti-ubiquitin antibodies. This result confirmed that viperin specifically stimulates IRAK1 ubiquitination, rather than causing a general increase in cellular protein ubiquitination (as discussed below) (Fig. 5, Fig. S6).

Interestingly, co-expression of TRAF6 with viperin did not change the level of IRAK1 ubiquitination significantly (Fig. 5). This suggests that the complex of viperin with IRAK1 either recruits endogenous TRAF6 and/or other E3 ubiquitin ligases to ubiquitinate IRAK1 (27, 36). Overall, the fraction of over-expressed IRAK1 converted to high molecular weight isoforms remained relatively small. This observation reflects the fact that ubiquitination is a dynamic process in which deubiquitination pathways also operate; furthermore, the high, non-physiological concentrations of IRAK1 produced by transfection may exceed the capacity of the cellular ubiquitination machinery. In contrast, the inactive viperin mutant failed to stimulate ubiquitination of IRAK1 (Fig. 5).

We note that the activation of IRAK1 by poly-ubiquitination has been shown to be essential for phosphorylation of IRF7, which is the penultimate step in TLR7/9 signaling (30, 31). Interestingly, very little ubiquitination of IRAK1 by TRAF6 was evident in the absence of viperin, even though these proteins were expressed at very high (nonphysiological) cellular concentrations (Fig. S6). This finding underscores the necessity of the interaction between viperin, IRAK1, and TRAF6 for ubiquitination of IRAK1 to occur.

Depleting cellular SAM levels reduces the half-life of viperin

To investigate whether SAM was required for viperin to stimulate poly-ubiquitination of IRAK1, we examined the effect of depleting cellular SAM levels using cycloleucine, which is an

Figure 4. Relocalization of IRAK1 and TRAF6 to the endoplasmic reticulum by viperin. 293T cells were transiently transfected with viperin and/or IRAK1 and TRAF6. 36 h post-transfection, cells were fixed in 4% paraformaldehyde, permeabilized with 0.05% Triton X-100, and immunostained for viperin, IRAK1, and TRAF6 as described under “Experimental procedures.” Images shown are representative of n = 10 cells. Scale bar = 5 μm. a, top panels: cells co-transfected with IRAK1 (red) and TRAF6 (green) show diffuse expression throughout the cell. Middle panels: cells were co-transfected with IRAK1, TRAF6, and viperin. Staining for viperin (green) and IRAK1 (red) demonstrates co-localization (yellow) of viperin and IRAK1. Bottom panels: cells were co-transfected with IRAK1, TRAF6, and viperin. Staining for viperin (green) and TRAF6 (red) demonstrates co-localization (yellow) of viperin and TRAF6. Co-expression of IRAK with viperin appears to result in IRAK1 also forming punctate structures that do not co-localize (middle panels). The reason for this is unclear. b, the re-localization of IRAK1 and TRAF6 to the ER induced by viperin was quantified, with the co-localization of IRAK1 and TRAF6 with the ER protein, calnexin, used as a measure of ER association. Top panel: the percentage of total IRAK1 that co-localizes to the ER in the presence or absence of viperin. Bottom panel: the percentage of total TRAF6 that co-localizes to the ER in the presence or absence of viperin. Results are presented as mean ± S.E. of at least 10 different cells.
inhibitor of SAM synthase (37). As discussed below, initial observations indicated that cycloleucine does inhibit the ubiquitination of IRAK1. However, when we investigated the effect of cycloleucine (50 mM) on the levels of cellular viperin, we observed that depletion of SAM with cycloleucine significantly reduced the half-life of viperin in the cells (Fig. 6a). This observation suggests that, as is typical of ligands that bind to proteins, the binding of SAM to viperin stabilizes its structure, as the half-life of cellular proteins is generally correlated with their stability (38–40). Therefore, the inhibition of IRAK1 ubiquitination by cycloleucine could be due either to reduced viperin levels, or a requirement for SAM.

We also examined the stability of the viperinΔ3C mutant, which is neither able to cleave SAM nor stimulate IRAK1 ubiquitination. When expressed in HEK293T cells, we found that viperinΔ3C had a significantly shorter half-life than WT viperin, even in the absence of cycloleucine (Fig. 6b). This observation suggested that removing the iron-sulfur cluster significantly destabilizes viperin’s structure, again leading to more rapid degradation.

To investigate the in vivo stability of viperinΔ3C further, we examined the effect of including sinefungin in the cell culture medium. Sinefungin is a tight-binding competitive inhibitor of many SAM-dependent enzymes (41), including radical SAM enzymes (42). We first confirmed that sinefungin binds to viperin by demonstrating that it acts as an effective inhibitor of both purified viperin (recombinantly expressed and purified from E. coli) and of viperin in lysates of transfected HEK 293T cells (Fig. S7). When HEK 293T cells transfected with viperinΔ3C were cultured in the presence of 50 mM sinefungin, the cellular stability of viperinΔ3C were restored to that of WT viperin (Fig. 5B). This observation implies that sinefungin stabilizes the structure of viperinΔ3C in the cell. Sinefungin treatment had no effect on the expression levels of WT viperin (Fig. S8).

These results suggest that both the iron-sulfur cluster and SAM contribute to the stability of viperin’s structure, thereby protecting it from degradation. The absence of the iron-sulfur cluster in viperinΔ3C presumably weakens or prevents SAM from binding, whereas sinefungin, which would not, in any case, coordinate to the iron-sulfur cluster, binds independently of the iron-sulfur cluster thereby explaining the stabilizing effect of sinefungin on viperinΔ3C.

Sinefungin restores the ability of viperinΔ3C to stimulate ubiquitination of IRAK1

The ability of sinefungin to stabilize the viperinΔ3C mutant in the cell, suggested that sinefungin might also restore the viperinΔ3C mutant’s ability to stimulate ubiquitination of IRAK1 by TRAF6. To test this hypothesis, HEK293T cells were co-transfected with either viperin or viperinΔ3C, IRAK1, and TRAF6 and 12 h post-transfection treated with either cycloleucine (50 mM) or sinefungin (50 mM, final concentration). The cells were cultured for a further 8 h, harvested, and IRAK1 was immunopurified from the cell extracts using anti-Myc-tagged magnetic beads. High molecular weight ubiquitinated forms of IRAK1 were then detected by immunoblotting with anti-ubiquitin antibody (Fig. 7a).

Consistent with the observations above, cycloleucine treatment resulted in no ubiquitination of IRAK1 in cells expressing either viperin or viperinΔ3C and IRAK1 and TRAF6 (Fig. 7b). However, sinefungin treatment significantly restored the ability of viperinΔ3C to stimulate ubiquitination of IRAK1, resulting in high molecular weight isoforms of IRAK1 (Fig. 7b). Importantly, this observation demonstrates that the stimulatory effect of viperin on IRAK1 ubiquitination does not depend on the radical-SAM activity of viperin per se.

The ability of sinefungin, a SAM mimic, to rescue the stimulatory activity of viperinΔ3C, suggested to us that 5′-dA, as the product of SAM cleavage, might inhibit viperin’s ability to stimulate poly-ubiquitination of IRAK1. To test this hypothesis, HEK 293T cells were co-transfected with WT viperin, TRAF6, and IRAK1 and treated with 5′-dA (5 mM final concentration). The treated cells were harvested after 12 h and IRAK1 was immunopurified from the cell extracts using anti-Myc-tagged beads, and then analyzed by immunoblotting for the presence of poly-ubiquitinated IRAK1. In this case, we observed that 5′-dA significantly reduced the level of poly-ubiquitinated Viperin regulates IRAK1 activation

Figure 5. Viperin stimulates ubiquitination of IRAK1. HEK 293T cells were transfected with genes encoding IRAK1, TRAF6, viperin, or viperinΔ3C as indicated. 30 h post-transfection cell lysates were prepared and analyzed by immunoprecipitation (IP) (IRAK1 as bait protein) followed by immunoblotting (IB) with anti-ubiquitin antibody. GAPDH was used as a loading control. A representative blot is shown. A significant increase in ubiquitated proteins is only observed in cells expressing viperin and IRAK1; viperinΔ3C fails to stimulate ubiquitination. Ubiquitination was quantified for each condition using ImageJ software and compared and presented as mean ± S.E. (n = 3) with *** indicating p < 0.001 (Student’s t test for independent samples).
Viperin regulates IRAK1 activation

Figure 6. Binding SAM stabilizes viperin in vivo.

a, HEK 293T cells were transfected with viperin and 20 h post-transfection 50 mM cycloleucine, a SAM synthase inhibitor, was added to the medium. At various time points cells were harvested and viperin expression was analyzed by immunoblotting (IB). Depletion of cellular SAM by cycloleucine significantly decreases viperin half-life. b, HEK 293T cells were transfected with viperinΔ3C and 12 h post-transfection 50 mM sinefungin was added to the medium. At various time points cells were harvested and viperin expression was analyzed by immunoblotting. Sinefungin stabilizes viperinΔ3C compared with DMSO control. Lower panels, band intensities were quantified relative GAPDH and expressed as mean ± S.D. from three independent experiments.

Figure 7. Effects of cycloleucine, 5′-dA, and sinefungin on poly-ubiquitination-stimulating activity of viperin.

a, flow chart describing the experimental protocol. b, cell lysates were immunoprecipitated with the Myc antibody (magnetic beads), followed by immunoblotting (IB) with anti-ubiquitin antibodies. Expression of transiently transfected proteins was confirmed by immunoblotting with c-Myc antibody. GAPDH served as a loading control. For WT viperin, cycloleucine or 5′-dA inhibit the ubiquitination of IRAK1; in contrast, sinefungin restores the ability of viperinΔ3C to stimulate the ubiquitination of IRAK1. c, quantification of IRAK ubiquitination levels obtained by integrating intensities of bands for blots using ImageJ software.

IRAK1 (Fig. 7b), suggesting that 5′-dA inhibits WT viperin’s ability to stimulate poly-ubiquitination of IRAK1. Control experiments established that 5′-dA is not a general inhibitor of protein ubiquitination, and that 5′-dA did not affect the expression of viperin, IRAK1, or TRAF6 (Fig. S9).

Discussion

The recent discovery that viperin catalyzes the synthesis of ddhCTP (20) has provided an important advance in our understanding of the mechanism by which viperin exerts its antiviral effects. However, although ddhCTP was shown to derive its antiviral effects by acting as an effective chain terminator of RNA-dependent RNA polymerases from flaviviruses, such as Zika virus, other RNA polymerases from RNA viruses that viperin is known to restrict were found to be insensitive to ddhCTP (20). Furthermore, in several cases the radical SAM activity of viperin appears to be dispensable for its antiviral activity (5, 21, 23).

A number of studies suggest that interactions between viperin and a variety of host and viral proteins are important for its antiviral effects, although the evidence has tended to rely on indirect measures of viperin’s activity such as the reduction of viral titer or viral RNA levels. By reconstituting the interactions between viperin, IRAK1, and TRAF6 in HEK 293T cells we have been able to examine a specific, biochemically well-defined function of viperin: the activation of IRAK1 by poly-ubiquitination. Our studies show that the enzymatic activity of viperin is increased by ~10-fold by co-expression with IRAK1 and TRAF6, whereas IRAK1 is not efficiently ubiquitinated in vitro unless viperin is also co-expressed. Thus, the activities of viperin and IRAK1 appear to be synergistically regulated activities, mediated through protein–protein interactions between viperin, IRAK1, and TRAF6.

Given viperin’s role as a component of the TLR7/9 signaling pathways it might be expected that other proteins in the pathway would regulate its antiviral activity. Regulation may prevent ddhCTP levels accumulating to the point where ddhCTP interferes with cellular RNA polymerases needed to transcribe other proteins involved in the antiviral response. The localization of viperin to the ER membrane and lipid bodies, which are the sites of flavivirus assembly (5, 43, 44), may enhance viperin’s
antiviral effect by insuring that ddhCTP is produced at high local concentrations at the site of viral RNA synthesis.

Although our studies have focused on viperin’s interactions with IRAK1 and TRAF6, evidence from other studies (7, 9, 21–25) indicates that there are many other proteins that interact with viperin and thus might similarly regulate its activity. The Fe-S cluster is required for viperin to catalyze the formation of ddhCTP; however, we have shown that the radical-SAM activity is not required for viperin to stimulate IRAK1 ubiquitination, because the stimulatory effect of the viperinΔ3C mutant can be rescued by the SAM analog, sinefungin. This dual function of viperin, importantly, resolves the numerous apparently contradictory observations, described above, regarding whether the radical-SAM activity of viperin is required for its antiviral effects.

Several small molecules perturb the viperin-dependent ubiquitination of IRAK1. The inhibitory effect of cycloleucine likely arises from the reduction of cellular SAM levels, as cycloleucine is an established inhibitor of SAM synthase (8, 37, 41, 42). We observed that in cycloleucine-treated cells viperin appears much less stable (Fig. 6a), arguing that binding SAM stabilizes the structure of viperin. In contrast, sinefungin both rescued the ubiquitination-stimulating activity of the viperinΔ3C mutant and appeared to stabilize the mutant enzyme against cellular degradation. Presumably, sinefungin binding repairs the structural deficit caused by removing the iron-sulfur from the enzyme.

It may be that the effects of cycloleucine and sinefungin on IRAK1 ubiquitination arise simply because they alter the cellular concentrations of viperin or viperinΔ3C. However, we consider it more likely that SAM and sinefungin alter the conformation of viperin, thereby allowing the enzyme to form a productive complex with IRAK1 and TRAF6. This idea is supported by the observation that the product of the viperin reaction, 5′-dA, inhibits the viperin-dependent ubiquitination of IRAK1. 5′-dA competes with SAM to bind viperin, but does not cause any significant change in the cellular stability of the enzyme.

Based on these observations we suggest that the reductive cleavage of SAM, and concomitant formation of ddhCTP, may serve as a mechanism by which viperin could regulate the ubiquitination of IRAK1 (Fig. 8). We propose that in the absence of SAM, viperin adopts a conformation that is unable to stimulate ubiquitination of IRAK1. Upon binding SAM, viperin undergoes a conformational change to an active state that stimulates K63-linked poly-ubiquitination of IRAK1 by TRAF6 (or other E3 ligases), eventually leading to transcription of type I interferons (27). Once the complex between IRAK1, TRAF6, and viperin is formed, viperin is activated to cleave SAM, thereby initiating the catalytic cycle leading to the formation of ddhCTP and 5′-dA. Completion of the catalytic cycle returns viperin to its inactive state, preventing further poly-ubiquitination of IRAK1.

Our measurements of viperin activity in cell extracts indicate that viperin converts CTP to ddhCTP with \( k_{\text{obs}} = 21.4 \pm 1.6 \, \text{h}^{-1} \), which is about twice as fast as in vitro kinetic data reported previously (20), but still rather slow by comparison with most enzyme reactions. However, the slow kinetics of viperin make this reaction well suited to regulate a signaling pathway in a manner analogous to signal regulation by heterotrimeric G proteins (45, 46). We note that, although consistent with our data, further studies with purified enzymes will be needed to validate this mechanistic proposal, which would constitute a new mode of regulating cellular protein activity by radical-SAM enzymes.

In conclusion, our experiments provide evidence for a regulatory mechanism that links the production of the newly identified antiviral nucleotide, ddhCTP, by viperin to transduction of innate immune signaling through K63-linked polyubiquitination of IRAK1 by TRAF6. In this manner, the up-regulation of various proteins that constitute the cellular antiviral

**Figure 8. Synergistic activation of viperin, IRAK1, and TRAF6 couples the production of antiviral ribonucleotides with innate immune signaling.** Clockwise from the top: binding of SAM and CTP to the viperin-IRAK1-TRAF6 complex activates the complex toward poly-ubiquitination of IRAK1. Activated viperin catalyzes the reaction of SAM with CTP to form 5′-dA and ddhCTP and concomitantly switches the complex from the ubiquitination-active state to ubiquitination-inactive state. Poly-ubiquitinated IRAK1 dissociates from the complex, leading to up-regulation of INF-1. For discussion see the text.
Viperin regulates IRAK1 activation

response is coordinated with the production of a small molecule inhibitor of viral replication. Protein ubiquitination plays multiple roles in cellular proteostasis and signal transduction (47, 48). We suggest that the wide-ranging roles that viperin plays in the antiviral response may, in part, result from the ability of the enzyme to recruit and activate a subset of the many E3 ubiquitin ligases present in the cell to ubiquitinate target proteins, thereby regulating their cellular levels in response to viral infection.

Experimental procedures

Cell lines

The HEK 293T cell line was obtained from ATCC.

Antibodies

Rabbit polyclonal RSAD2/viperin antibody (11833-1-AP) was obtained from Protein Tech. Rabbit polyclonal IRAK1 antibody (PA5-17490) was obtained from Thermo Scientific. Rabbit polyclonal ubiquitin antibody (sc-9133) and mouse monoclonal TRAF6 antibody (sc-8409) were purchased from Santa Cruz. Goat anti-rabbit (170-6515) and anti-mouse (626520) Ig secondary Abs were purchased from Bio-Rad and Life Technologies, respectively. Rabbit polyclonal GAPDH (TAB1001) was purchased from Thermo Scientific and mouse monoclonal GAPDH antibody (6C5) was obtained from EMD Millipore.

Plasmids

Synthetic genes encoding human viperin, IRAK1, and TRAF6 (GenBank™ accession numbers AAL50053.1, NM145803, and NM001569, respectively) were purchased from GenScript. For details see supplemental information.

Reagents

The sources of other reagents were as described previously (23). Sinefungin (567051-2MG-M) was purchased from Sigma. Nucleotide substrates are listed and purchased from: ATP (ATP disodium salt trihydrate) Fisher Scientific, BP413-25; GTP (GTP sodium salt hydrate ≥95%) Sigma, G8877; UTP (UTP, trisodium salt hydrate, 90%) Acros Organics, AC226310010; and CTP (CTP, disodium salt hydrate, 95%) Acros Organics, 226225000. Deuterium-labeled ATP (adenosine-2,8-d2,1′,2′,3′,4′,5′,5′-d6 5′-triphosphate sodium salt, 738034-1MG) and CTP (cytidine-5,6-d2,1′,2′,3′,4′,5′,5′-d6 5′-triphosphate sodium salt, 738042-1MG) were purchased from Sigma. Pierce™ anti-c-Myc magnetic beads (88842) were purchased from ThermoFisher Scientific.

Transfection

HEK 293T cells, cultured as described above, were transiently transfected using FuGENE® HD (Promega) following the manufacturer’s instructions.

Immunofluorescence analyses

Cells were grown on poly-L-lysine–coated coverslips to 30–40% confluence, transfected with plasmids expressing viperin, IRAK1, and/or TRAF6, and incubated for 30 h. Cells were fixed with 4% paraformaldehyde, permeabilized with 0.05% Triton X-100 dissolved in PBS, and washed three times with PBS containing 0.1% Tween 20. The fixed cells were stained with the appropriate antibodies. Primary antibodies were diluted in PBS containing, 1% fetal bovine serum and 0.1% Tween 20. Viperin was detected by using mouse monoclonal anti-viperin (Abcam) diluted 1:250, and calnexin was detected with rabbit polyclonal antibody (Abcam) diluted 1:250. IRAK1 was detected by using rabbit polyclonal IRAK1 antibody (Thermo Scientific) diluted 1:250 and mouse monoclonal c-Myc tag antibody (Thermo Scientific) diluted 1:100. TRAF6 was detected by using mouse monoclonal TRAF6 antibody (Santa Cruz) diluted 1:100. After incubation at room temperature for 1 h or overnight at 4 °C, the coverslips were washed with PBS containing 0.1% Tween 20 and treated with Alexa Fluor 647-conjugated goat anti-mouse (Life Technologies) and Alexa Fluor 488-conjugated goat anti-rabbit (Abcam) secondary antibodies at a dilution of 1:400 at room temperature for 2 h. The coverslips were washed three times with PBS containing 0.1% Tween 20 and mounted in ProLong™ Gold Antifade Mountant (Molecular Probes). Images were acquired with an Olympus IX81 microscope with a ×60 1.49NA objective on an Andor iXON Ultra EMCCD camera. 488 nm (Coherent Cube 488–50) and 640 nm (Coherent Cube 640–100) laser excitation was aligned in HILO imaging mode for axial sectioning using an Olympus cell∧TIRF module.

Immunoblotting

Cells were lysed in TBST buffer (20 mM Tris, pH 7.5, 500 mM NaCl, 0.05% Tween 20) containing protease inhibitors (SIGMAFAST™ Protease Inhibitor Tablets, S8830; Sigma). Supernatants of lysates were collected and mixed with reducing sample buffer. The supernatants were separated on 10% SDS-PAGE gels. The bicinchoninic acid assay (Thermo Scientific) was used to determine the total amount of protein in the lysates. Immunoblotting was performed as described previously (23). Primary antibodies used were directed against viperin (rabbit polyclonal diluted 1:2500), GAPDH (rabbit polyclonal diluted 1:5000), IRAK1 (rabbit polyclonal diluted 1:4000), TRAF6 (mouse monoclonal diluted 1:500), and GAPDH (mouse monoclonal diluted 1:5000). Rabbit polyclonal ubiquitin antibody was used at a dilution of 1:1000. Blots were visualized, and band intensities quantified using a Bio-Rad ChemiDoc Touch imaging system. Integrated density measurements were done using ImageJ software. Quantitative measurements of protein expression levels reported here represent the average of at least three independent biological replicates.

Immunoprecipitation assays

Cells were rinsed twice with ice-cold PBS, harvested in Nonidet P-40 lysis buffer (50 mM Tris, pH 7.4, 1% Triton X-100, 150 mM NaCl, 10% glycerol, 1 mM EDTA, 10 mM NaF, 0.1% NP-40 and 0.2 mM phenylmethylsulfonyl fluoride with protease inhibitor cocktail from Sigma), and briefly sonicated. Lysates were collected by centrifugation at 12,000 × g for 15 min at 4 °C. For immunoprecipitation, the ratio of suspension to packed gel volume was 2:1. Resin pre-equilibration was done as per the manufacturer’s protocol. Three hundred microliters of a 1:1:1 ratio of cell lysates was added and incubated for 16 h at 4 °C with gentle rotation. Beads were pelleted by centrifugation at
5,000 × g for 30 s at 4 °C and washed three times with washing buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 10% glycerol, 1 mM EDTA, 10 mM NaF, and 0.2 mM phenylmethylsulfonyl fluoride with protease inhibitor mixture from Sigma). Immunocomplexes were eluted by boiling in SDS-PAGE sample buffer, separated by SDS-PAGE, and transferred to a nitrocellulose membrane. Immunoprecipitation using Protein A beads or anti-Myc-tagged magnetic beads was performed as per the manufacturers protocol. Membranes were blocked for 2 h at room temperature in TBST buffer (20 mM Tris, pH 7.5, 137 mM NaCl, and 0.1% Tween 20) containing 5% nonfat dry milk, followed by overnight incubation at 4 °C in TBST buffer containing 3% nonfat dry milk and the appropriate primary antibody. Membranes were washed three times in TBST and then incubated for 2 h at room temperature with the secondary IgG-coupled horseradish peroxidase antibody. The membranes were washed three times with TBST, and the signals were visualized with enhanced chemiluminescence reagent as described under “Immunoblotting.”

Statistical analyses

Results from all studies were compared with unpaired two-tailed Student’s t test using GraphPad Prism 5 software. p values less than 0.05 were considered significant.

Assay of viperin in HEK 293T cell lysates

HEK 293T cells transfected with viperin, and/or IRAK1 and TRAF6 were harvested from one 10-cm diameter tissue culture plate each, resuspended in 500 μl of anoxic TBS (50 mM Tris-Cl, pH 7.6, 150 mM NaCl) containing 1% Triton X-100, sonicated within an anaerobic glovebox (Coy Chamber), and centrifuged at 14,000 × g for 10 min. DTT (5 mM) and dithionite (5 mM) were added to the cell lysate together with CTP (300 μM). The assay mixture was incubated at room temperature for 30 min prior to starting the reaction by the addition of SAM (200 μM). The assay was incubated for 60 min at room temperature, after which the reaction was stopped by heating at 95 °C for 10 min. The solution was chilled to 4 °C, and the precipitated proteins were removed by centrifugation at 14,000 rpm for 25 min. The supernatant was then extracted with acetonitrile. Samples were analyzed in triplicate by UPLC-tandem MS as described previously (23). For details of standard curve construction and calculations refer to supporting Information.

Author contributions—A. B. D. data curation; A. B. D., S. G., K. A. Z., and J. D. H. investigation; A. B. D., S. G., P. A. M., and J. D. H. methodology; A. B. D. and E. N. G. M. writing-original draft; A. B. D. and E. N. G. M. writing-review and editing; S. G. and R. T. K. resources; K. A. Z. and P. A. M. formal analysis; J. D. H. visualization; R. T. K. and E. N. G. M. supervision; R. T. K. and E. N. G. M. funding acquisition; R. T. K. and E. N. G. M. project administration; E. N. G. M. conceptualization.

References

1. Wu, J. X., and Chen, Z. J. (2014) Innate immune sensing and signaling of cytosolic nucleic acids. Annu. Rev. Immunol. 32 461–488
2. Chin, K. C., and Cresswell, P. (2001) Viperin (cig5), an IFN-inducible antiviral protein directly induced by human cytomegalovirus. Proc. Natl. Acad. Sci. U.S.A. 98, 15125–15130 CrossRef Medline
3. Helbig, K. J., and Beard, M. R. (2014) The role of viperin in the innate antiviral response. J. Mol. Biol. 426, 1210–1219 CrossRef Medline
4. Seo, J. Y., Yaneva, R., and Cresswell, P. (2011) Viperin: a multifunctional, interferon-inducible protein that regulates virus replication. Cell Host Microbe 10, 534–539 CrossRef Medline
5. Helbig, K. J., Carr, J. M., Calvert, J. K., Wati, S., Clarke, J. N., Eyre, N. S., Narayana, S. K., Fiches, G. N., McCartney, E. M., and Beard, M. R. (2013) Viperin is induced following dengue virus type-2 (denv-2) infection and has anti-viral actions requiring the C-terminal end of viperin. PLoS Negl. Trop. Dis. 7, e2178 CrossRef Medline
6. Nasr, N., Maddocks, S., Turville, S. G., Harman, A. N., Woolger, N., Helbig, K. J., Wilkinson, J., Bye, C. R., Wright, T. K., Rambukwelle, D., Donaghy, H., Beard, M. R., and Cunningham, A. L. (2012) HIV-1 infection of human macrophages directly induces viperin which inhibits viral production. Blood 120, 778–788 CrossRef Medline
7. Helbig, K. J., Eyre, N. S., Yip, E., Narayana, S., Li, K., Fiches, G., McCartney, E. M., Angra, R. K., Lemon, S. M., and Beard, M. R. (2011) The antiviral protein viperin inhibits hepatitis c virus replication via interaction with nonstructural protein 5a. Hepatology 54, 1506–1517 CrossRef Medline
8. Upadhyay, A. S., Vonderstein, K., Pichmlair, A., Stehling, O., Bennett, K. L., Dobler, G., Guo, J. T., Superti-Furga, G., Lill, R., Overby, A. K., and Weber, F. (2014) Viperin is an iron-sulfur protein that inhibits genome synthesis of tick-borne encephalitis virus via radical SAM domain activity. Cell Microbiol. 16, 834–848 CrossRef Medline
9. Panayiotou, C., Lindqvist, R., Kurhade, C., Vonderstein, K., Pasto, J., Edlund, K., Upadhyay, A. S., and Overby, A. K. (2018) Viperin restricts Zika virus and tick-borne encephalitis virus replication by targeting NS3 for proteasomal degradation. J. Virolology 92, e02054–17 CrossRef Medline
10. Fenwick, M. K., Li, Y., Cresswell, P., Modis, Y., and Ealick, S. E. (2017) Structural studies of viperin, an antiviral radical SAM enzyme. Proc. Natl. Acad. Sci. U.S.A. 114, 6806–6811 CrossRef Medline
11. Haldar, S., Paul, S., Joshi, N., Dasgupta, A., and Chattopadhyay, K. (2012) The presence of the iron-sulfur motif is important for the conformational stability of the antiviral protein, viperin. PLoS ONE 7, e31797 CrossRef Medline
12. Shaveta, G., Shi, J., Chow, V. T., and Song, J. (2010) Structural characterization reveals that viperin is a radical S-adenosyl-l-methionine (SAM) enzyme. Biochem. Biophys. Res. Commun. 391, 1390–1395 CrossRef Medline
13. Hinson, E. R., and Cresswell, P. (2009) The N-terminal amphipathic α-helix of viperin mediates localization to the cytosolic face of the endoplasmic reticulum and inhibits protein secretion. J. Biol. Chem. 284, 4705–4712 CrossRef Medline
14. Landgraf, B. J., McCarthy, E. L., and Booker, S. J. (2016) Radical S-adenosylmethionine enzymes in human health and disease. Annu. Rev. Biochem. 85, 485–514 CrossRef Medline
15. Broderick, J. B., Duffus, B. R., Duschene, K. S., and Shepard, E. M. (2014) Radical S-adenosylmethionine enzymes. Chem. Rev. 114, 4229–4317 CrossRef Medline
16. Marsh, E. N., Patwardhan, A., and Huhta, M. S. (2004) S-Adenosylmethionine radical enzymes. Bioorg. Chem. 32, 326–340 CrossRef Medline
17. Frey, P. A., Hegeman, A. D., and Ruzicka, F. J. (2008) The radical SAM superfamily. Crit. Rev. Biochem. Mol. Biol. 43, 63–88 CrossRef Medline
18. Vey, J. L., and Drennan, C. L. (2011) Structural insights into radical generation by the radical SAM superfamily. Chem. Rev. 111, 2487–2506 CrossRef Medline
19. Wang, J., Wolding, R. P., Román-Melendez, G. D., McClain, A. M., Alzu, B. R., and Marsh, E. N. (2014) Recent advances in radical SAM enzymology: new structures and mechanisms. ACS Chem. Biol. 9, 1929–1938 CrossRef Medline
20. Gizzit, A. S., Grove, T. L., Arnold, J. J., Jose, J., Jangra, R. K., Garforth, S. I., Du, Q., Cahill, S. M., Dulyaninova, N. G., Love, J. D., Chandran, K., Bresnick, A. R., Cameron, C. E., and Almo, S. C. (2018) A naturally occurring antiviral ribonucleotide encoded by the human genome. Nature 558, 610–614 CrossRef Medline
21. Vonderstein, K., Nilsson, E., Hubel, P., Nygard Skalman, L., Upadhyay, A., Pasto, J., Pichmlair, A., Lundmark, R., and Overby, A. K. (2017) Viperin regulates IRAK1 activation.
Viperin regulates IRA1 activation

targets flavivirus virulence by inducing assembly of non-infectious capsid particles. J. Virol. 92, e01751–17 Medline

22. Wang, X., Hinson, E. R., and Cresswell, P. (2007) The interferon-inducible protein viperin inhibits influenza virus release by perturbing lipid rafts. Cell Host Microbe 2, 96–105 CrossRef Medline

23. Makins, C., Ghosh, S., Román-Melendez, G. D., Malec, P. A., Kennedy, R. T., and Marsh, E. N. (2016) Does viperin function as a radical S-adenosyl-1-methionine-dependent enzyme in regulating farnesylpyrophosphate synthase expression and activity? J. Biol. Chem. 291, 26806–26815 CrossRef Medline

24. Seo, J. Y., Yaneva, R., Hinson, E. R., and Cresswell, P. (2011) Human cyto-megalovirus directly induces the antiviral protein viperin to enhance infectivity. Science 332, 1093–1097 CrossRef Medline

25. Wang, S., Wu, X., Pan, T., Song, W., Wang, Y., Zhang, F., and Yuan, Z. (2012) Viperin inhibits hepatitis C virus replication by interfering with binding of NSSA to host protein hVAP-33. J. Gen. Virol. 93, 83–92 CrossRef Medline

26. Jiang, X., and Chen, Z. J. (2011) Viperin links lipid bodies to immune defense. Immunity 34, 285–287 CrossRef Medline

27. Saitoh, T., Satoh, T., Yamamoto, N., Uematsu, S., Takeuchi, O., Kawai, T., and Akira, S. (2011) Antiviral protein viperin promotes Toll-like receptor 7- and Toll-like receptor 9-mediated type I interferon production in plasmacytoid dendritic cells. Immunity 34, 352–363 CrossRef Medline

28. Wang, L., Qiao, Q., Ferrao, R., Shen, C., Hatcher, J. M., Buhrlage, S. J., Gray, N. S., and Wu, H. (2017) Crystal structure of human IRAK1. Proc. Natl. Acad. Sci. U.S.A. 114, 13507–13512 CrossRef Medline

29. Conze, D. B., Wu, C. J., Thomas, J. A., Landstrom, A., and Ashwell, J. D. (2008) Lys63-linked polyubiquitination of IRAK-1 is required for interleukin-1 receptor- and Toll-like receptor-mediated NF-κB activation. Mol. Cell Biol. 28, 3538–3547 CrossRef Medline

30. Honda, K., Yanai, H., Mizutani, T., Negishi, H., Shimada, N., Suzuki, N., Ohba, Y., Takaoaka, A., Yeh, W. C., and Taniguchi, T. (2004) Role of a transductional-transcriptional processor complex involving MyD88 and IRF-7 in Toll-like receptor signaling. Proc. Natl. Acad. Sci. U.S.A. 101, 15416–15421 CrossRef Medline

31. Honda, K., Takaoaka, A., and Taniguchi, T. (2006) Type I interferon gene induction by the interferon regulatory factor family of transcription factors. Immunity 25, 349–360 CrossRef Medline

32. Fu, T. M., Shen, C., Li, Q., Zhang, P., and Wu, H. (2018) Mechanism of ubiquitin transfer promoted by TRAF6. Proc. Natl. Acad. Sci. U.S.A. 115, 1783–1788 CrossRef Medline

33. Ye, H., Arron, J. R., Lamothe, B., Cirilli, M., Kobayashi, T., Shevde, N. K., Segal, D., Dzivenu, O. K., Vologodskia, M., Yim, M., Du, K., Singh, S., Pike, J. W., Darnay, B. G., Choi, Y., and Wu, H. (2002) Distinct molecular mechanism for initiating TRAF6 signalling. Nature 418, 443–447 CrossRef Medline

34. Hinson, E. R., and Cresswell, P. (2009) The antiviral protein, viperin, localizes to lipid droplets via its N-terminal amphipathic α-helix. Proc. Natl. Acad. Sci. U.S.A. 106, 20452–20457 CrossRef Medline

35. Blasius, A. L., and Beutler, B. (2010) Intracellular Toll-like receptors. Immunity 32, 305–315 CrossRef Medline

36. Orduereu, A., Smith, H., Windheim, M., Peggie, M., Carrick, E., Morrice, N., and Cohen, P. (2008) The IRAK-catalysed activation of the E3 ligase function of pellelino isoforms induces the Lys63-linked polyubiquitination of IRAK1. Biochem. J. 409, 43–52 CrossRef Medline

37. Caboche, M., and Hatzfeld, J. (1978) Methionine metabolism in BHK cells: preliminary characterization of physiological-effects of cycloleucine, an inhibitor of S-adenosylmethionine biosynthesis. J. Cell Physiol. 97, 361–370 CrossRef Medline

38. Parsell, D. A., and Sauer, R. T. (1989) The structural stability of a protein is an important determinant of its proteolytic susceptibility in Escherichia coli. J. Biol. Chem. 264, 7590–7595 Medline

39. Foit, L., Morgan, G. J., Kern, M. J., Steimer, L. R., von Hacht, A. A., Titchmarsh, J., Warriner, S. L., Radford, S. E., and Bardwell, J. C. A. (2009) Optimizing protein stability in vivo. Mol. Cell 36, 861–871 CrossRef Medline

40. Sanchez-Ruiz, J. M. (2010) Protein kinetic stability. Biophys. Chem. 148, 1–15 CrossRef Medline

41. Borchardt, R. T., Eiden, L. E., Wu, B., and Rutledge, C. O. (1979) Sinefungin, a potent inhibitor of S-adenosylmethionine-protein O-methyltransferase. Biochem. Biophys. Res. Commun. 89, 919–924 CrossRef Medline

42. Farrar, C. E., Siu, K. K., Howell, P. L., and Jarrett, J. T. (2010) Biotin synthase exhibits burst kinetics and multiple turnovers in the absence of inhibition by products and product-related biomolecules. Biochemistry 49, 9985–9996 CrossRef Medline

43. Fitzgerald, K. A. (2011) The interferon inducible gene: vaperin. J. Interferon Cytokine Res. 31, 131–135 CrossRef Medline

44. Peña CárCamo, J. R., Morell, M. L., Vázquez, C. A., Vatansever, S., Uparhy, A. S., Overby, A. K., Cordo, S. M., and García, C. C. (2018) The interplay between vaperin antiviral activity, lipid droplets and junin mamavenous multiplication. Virology 514, 216–229 CrossRef Medline

45. Neer, E. J. (1995) Heterotrimeric G-proteins: organizers of transmembrane signals. Cell 80, 249–257 CrossRef Medline

46. Dohlman, H. G., and Thorner, J. (1997) GαS proteins and signaling by heterotrimeric G proteins. J. Biol. Chem. 272, 3871–3874 CrossRef Medline

47. Bhoj, V. G., and Chen, Z. I. (2009) Ubiquitination in innate and adaptive immunity. Nature 458, 430–437 CrossRef Medline

48. Hu, H., and Sun, S. C. (2016) Ubiquitin signaling in innate responses. Cell Res. 26, 457–483 CrossRef Medline